Matrix metalloproteinase-9 and paraoxonase 1 Q/R192 gene polymorphisms and the risk of coronary artery stenosis in Iranian subjects

Journal of Clinical Laboratory Analysis

Volumn 24, Issue 5, 2010, Pages 305-310

  Fallah, Soudabeh ^a   Seifi, Morteza ^a   Ghasemi, Asghar ^a   Firoozrai, Mohsen ^a   Samadikuchaksaraei, Ali ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Coronary artery stenosis; Matrix metalloproteinase 9; Paraoxonase 1; Polymerase chain reaction; Restriction fragment length polymorphism

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; GELATINASE B;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DISEASE SEVERITY; DNA POLYMORPHISM; ENZYME LOCALIZATION; ENZYME POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEX DIFFERENCE;

ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; CORONARY STENOSIS; FEMALE; HUMANS; IRAN; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROGNOSIS; RISK FACTORS; SURVIVAL RATE;

EID: 77957273007     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20406     Document Type: Article

References (41)

1. Huang Y, Mironova M, Lopes-Virella MF. Oxidized LDL stimulates matrix metalloproteinase-1 expression in human vascular endothelial cells. Arterioscler Thromb Vasc Biol 1999;19: 2640-2647.
2. Navab M, Berliner JA, Watson AD, et al. The yin and yang of oxidation in the development of fatty streak: a review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 1996;16:831-842.
3. Mackness MI, Durrington PN. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995;115:243-253.
4. Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990;1044:275-283.
5. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991;286:152-154.
6. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high density lipoprotein associated paraoxonase. Atherosclerosis 1993; 104:129-135.
7. Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995;96:2882-2891.
8. Watson AD, Navab M, Hama SY, et al. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 1995;95: 774-782.
9. Vohl MC, Neville TA, Kumarathasan R, Braschi S, Sparks DL. A novel lecithin-cholesterol acyltransferase antioxidant activity prevents the formation of oxidized lipids during lipoprotein oxidation. Biochemistry 1999;38:5976-5981.
10. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21:473-480.
11. Leviev I, James RW. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 2000;20:516-552.
12. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005;85:1-31.
13. Galis ZS, Johnson C, Godin D, et al. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration arterial remodeling and geometrical. Circ Res 2002;91: 852-859.
14. Luttun A, Lutgens E, Manderveld A, et al. Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation 2004;109: 1408-1414.
15. Morgan AR, Zhang B, Tapper W, Collins A, Ye S. Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease. J Mol Med 2003;81:321-326. (Pubitemid 36718329)
16. Zhang B, Ye S, Herrmann SM, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999;99:1788-1794.
17. Friedewald WT, Levi IR, Fredrickson DS. Estimation of low density lipoprotein cholesterol levels in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
18. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human ucleated cells. Nucleic Acid Res 1988;16:1215.
19. Pollanen PJ, Karhunen PJ, Mikkelsson J, et al. Coronary artery complicated lesion area is related to functional polymorphism of matrix metalloproteinase 9 gene: An autopsy study. Arterioscler Thromb Vasc Biol 2001;21:1446-1450.
20. Cho HJ, Chae IH, Park KW, et al. Functional polymorphism in the promoter region of the gelatinase B gene in relation to coronary artery disease and restenosis after percutaneous coronary intervention. J Hum Genet 2002;47:88-91.
21. Medley TL, Cole TJ, Dart AM, Gatzka CD, Kingwell BA. Matrix metallaproteinase-9 genotype influences large artery stiffness through effects on aortic gene and protein expression. Arterioscler Thromb Vasc Biol 2004;24:1479-1484.
22. Johnson C, Galis ZS. Matrix metalloproteinase-2 and-9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler Thromb Vasc Biol 2004;24: 54-60. (Pubitemid 38082411)
23. Yasmin S, Wallace S, McEniery CM, et al. Matrix metalloproteinase- 9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005;25:372.
24. Johnson C, Galis ZS. Matrix metalloproteinase-2 and-9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler Thromb Vasc Biol 2004;24: 54-60.
25. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993;3:73-76.
26. Mackness MI, Arrol S, Mackness B, Durrington PN. The alloenzymes of paraoxonase determine the effectiveness of highdensity lipoprotein in protecting low density lipoprotein against lipid-peroxidation. Lancet 1997;349:851-852.
27. Aviram M, Hardk E, Vaya J, et al. Human serum paraoxonase (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid arteriosclerotic lesions. Circulation 2000;101: 2510-2517.
28. Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 2005;69:541-550.
29. Pollanen PJ, Karhunen PJ, Mikkelsson J, et al. Coronary artery complicated lesion area is related to functional polymorphism of matrix metalloproteinase 9 gene: An autopsy study. Arterioscler Thromb Vasc Biol 2001;21:1446-1450.
30. Cho HJ, Chae IH, Park KW, et al. Functional polymorphism in the promoter region of the gelatinase B gene in relation to coronary artery disease and restenosis after percutaneous coronary intervention. J Hum Genet 2002;47:88-91.
31. Medley TL, Cole TJ, Dart AM, Gatzka CD, Kingwell BA. Matrix metallaproteinase-9 genotype influences large artery stiffness through effects on aortic gene and protein expression. Arterioscler Thromb Vasc Biol 2004;24:1479-1484.
32. Ranade K, Kirchgessner TG, Iakoubova OA, et al. Evaluation of the paraoxonases as candidate genes for stroke: Gln192Arg polymorphism 1 gene is associated with increased risk of stroke. Strock 2005;36:2346-2350.
33. Ozkok E, Aydin M, Babalik E, Ozbek Z, Ince N, Kara I. Combined impact of matrix metalloproteinase-3 andparaoxonase 1 55/192 gene variants on coronaryartery disease in Turkish patients. Med Sci Monit 2008;14:536-542.
34. Pasdar A, Ross-Adams H, Cumming A, et al. Paraoxonase gene polymorphisms and haplotype analysis in a stroke population. BMC Med Genet 2006;7:28-34.
35. Flekac M, Skraha J, Zidkova K, Lacinova Z, Hilgertova J. Paraoxonase 1 gene polymorphisms and enzyme activities in diabetes mellitus. Physiol Res 2008;57:717-726.
36. Koda Y, Tachida H, Soejima M, Takenaka O, Kimura H. Population differences in DNA sequence variation and linkage disequilibrium at the PON1 gene. Ann Hum Genet 2004;68:110-119. (Pubitemid 38379842)
37. Irace C, Cortese C, Fiaschi E, et al. The influence of PON1 192 polymorphism on endothelial function in diabetic subjects with or without hypertension. Hypertens Res 2008;31:507-513.
38. Gaidukov L, Rosenblat M, Aviram M, Tawfik DS. The 192R/Q polymorphs of serum paraoxonase PON1differ in HDL binding, lipolactonase stimulation, and cholesterol efflux. Lipid Res 2006; 47:2492-2502.
39. Khersonsky O, Tawfik DS. The histidine 115-histidine134 dyad mediates the lactonase activity of mammalian serum paraoxonases. Biol Chem 2006;281:7649-7656.
40. Bhattacharyya T, Nicholls SJ, Topol EJ, et al. Relationship of Paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. J Am Med Assoc 2008;299:1265-1276.
41. Lusis AJ, Mar R, Pajukanta P. Genetics of atherosclerosis. Annu Rev Genomics Hum Genet 2004;5:189-218.